PMHNP Psychopharmacology:
Medication Guide for Board Exam Prep

Pharmacology is not a single domain on either exam. It is distributed across multiple content areas, which means it appears throughout the test, not in one predictable block.

ANCC PMHNP-BC: Pharmacology questions concentrate in Diagnosis and Treatment (22% of the exam) and Scientific Foundation (22%). The Diagnosis and Treatment domain tests your ability to select appropriate medications, manage side effects, and adjust treatment when the first-line agent fails. The Scientific Foundation domain tests receptor pharmacology, mechanisms of action, pharmacokinetics, and drug interactions. Pharmacology knowledge also appears in Advanced Practice Skills (monitoring, lab interpretation) and Ethics (informed consent for medication, off-label prescribing).

AANPCB PMHNP-C: Pharmacology is heaviest in Plan (26% of the exam) and Evaluate (20%). The Plan domain tests treatment selection: choosing the right medication for the right patient with the right comorbidities. The Evaluate domain tests whether the treatment is working: expected timelines, monitoring parameters, when to switch or augment, and managing adverse effects. Pharmacology also appears in Assess (medication history, current medications, interactions) and Diagnose (substance-induced presentations, medication-related differential diagnoses).

The practical implication: you cannot compartmentalize pharmacology into a single study block. It intersects with diagnosis, treatment planning, monitoring, and clinical reasoning. The drug class sections below are organized to reflect those intersections.

SSRIs (Selective Serotonin Reuptake Inhibitors)

First-line for major depressive disorder, generalized anxiety disorder, panic disorder, OCD, PTSD, and social anxiety disorder. The broadest indication range of any antidepressant class. Board exams test your ability to differentiate between individual SSRIs based on their unique clinical profiles, not just “start an SSRI.”

What boards test: SSRI selection based on patient-specific factors (age, comorbidities, drug interactions, side effect profile), serotonin syndrome recognition and management, discontinuation syndrome (especially with paroxetine and venlafaxine), CYP450 interactions (fluoxetine and paroxetine are potent CYP2D6 inhibitors), use in pregnancy (sertraline has the most safety data), and the FDA boxed warning for suicidal ideation in patients under 25.

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

Dual-mechanism antidepressants that add noradrenergic activity to serotonergic activity. Clinically useful when SSRIs provide incomplete response, when comorbid pain is present (duloxetine has FDA approval for chronic pain conditions), or when fatigue and psychomotor retardation are prominent symptoms suggesting noradrenergic deficit.

What boards test: SNRI vs SSRI selection rationale, dose-dependent norepinephrine activity (venlafaxine is essentially an SSRI at low doses), blood pressure monitoring with venlafaxine (dose-dependent hypertension), duloxetine for comorbid pain conditions, and discontinuation syndrome (venlafaxine has one of the shortest half-lives and highest discontinuation risk of any antidepressant).

Other Antidepressants

Several antidepressants fall outside the SSRI/SNRI categories and are heavily board-tested because their unique mechanisms create specific clinical niches.

Atypical (Second-Generation) Antipsychotics

First-line for most psychotic disorders and bipolar disorder. Lower EPS risk than typicals (though not zero). Higher metabolic risk (weight gain, diabetes, dyslipidemia), varying by agent. Board exams expect you to know which atypicals carry the highest metabolic burden (olanzapine, clozapine) vs the most metabolically neutral options (aripiprazole, ziprasidone, lurasidone).

Typical (First-Generation) Antipsychotics

Higher D2 affinity produces more EPS and prolactin elevation but remains useful for acute agitation, treatment-resistant cases, and long-acting injectable formulations. Board exams test EPS recognition (acute dystonia, akathisia, parkinsonism, tardive dyskinesia), NMS recognition, and the role of first-generation agents in acute settings.

Lithium vs valproate: which mood stabilizer and when. Lithium is the gold standard for classic euphoric mania, has the strongest maintenance evidence, and is the only mood stabilizer with demonstrated anti-suicidal properties. Valproate is often preferred for rapid cycling, mixed episodes, and when a broader anticonvulsant profile is needed. Lithium requires renal and thyroid monitoring; valproate requires hepatic monitoring. Both are teratogenic, but valproate carries higher risk (neural tube defects) and should be avoided in women of childbearing potential when alternatives exist. Lamotrigine occupies a different niche entirely: it is for bipolar depression prevention, not acute mania.

Stimulant vs non-stimulant: how to choose. Stimulants (methylphenidate, amphetamine salts) are first-line for ADHD in most patients. They work faster (days, not weeks), have higher response rates, and have decades of evidence. Non-stimulants (atomoxetine, guanfacine, clonidine) are appropriate when stimulants are contraindicated (active substance use disorder, uncontrolled cardiovascular disease, tic disorders worsened by stimulants), when the patient prefers a non-controlled option, or when stimulant side effects are intolerable. Non-stimulants take weeks to reach full effect and generally produce more modest symptom improvement. The choice is driven by patient risk profile and comorbidities, not by a blanket “try stimulants first” rule.

Trap 1: Starting an antidepressant in unrecognized bipolar disorder. A patient presents with depression. You start an SSRI. Six weeks later they are manic. The exam tests whether you screened for bipolar before prescribing. Antidepressant monotherapy in bipolar disorder risks manic switch, mixed features, and cycle acceleration. Every patient presenting with depression needs bipolar screening before starting an antidepressant. This is the single most consequential prescribing error in mood disorders.

Trap 2: Choosing the wrong SSRI for a specific patient. The exam does not ask "name an SSRI." It gives you a 28-year-old pregnant woman with depression and asks which SSRI. Or a 70-year-old on multiple medications and asks which SSRI has the fewest drug interactions. Or an adolescent and asks which SSRI has FDA approval for that age group. The answer depends on the patient: sertraline for pregnancy, sertraline or escitalopram for drug interaction concerns, fluoxetine for adolescents. "Start an SSRI" is not a complete answer.

Trap 3: Failing to recognize serotonin syndrome. A patient on an SSRI is started on tramadol (a weak serotonin reuptake inhibitor) for pain and develops agitation, clonus, hyperthermia, and diaphoresis. The exam tests whether you recognize this as serotonin syndrome vs NMS vs other causes of altered mental status. Key distinguishing features: serotonin syndrome has clonus and hyperreflexia; NMS has lead-pipe rigidity and elevated CK. Serotonin syndrome is caused by serotonergic drug combinations. NMS is caused by dopamine blockade (antipsychotics). Both are emergencies. The clinical reasoning is different.

Trap 4: Treating "treatment-resistant depression" without verifying the basics. A patient has "failed" two SSRIs. The tempting answer is augmentation or ketamine. The correct first step: verify that each trial was adequate (therapeutic dose, sufficient duration, confirmed adherence) and that the diagnosis is actually MDD (not bipolar, not substance-induced, not a medical condition, not a personality disorder maintaining the depressive symptoms). Most "treatment-resistant depression" is under-investigated depression.

Trap 5: Missing the clozapine indication. A patient with schizophrenia has failed two adequate antipsychotic trials. The exam answer is clozapine. Not a third atypical. Not an antipsychotic combination. Not a mood stabilizer augmentation. Clozapine is the standard of care for treatment-resistant schizophrenia. It is the most underused antipsychotic in practice because of monitoring requirements, but the board exam expects you to know when it is indicated and to choose it without hesitation.

Psychopharmacology feels overwhelming because the volume of material is large. But board exams do not test your ability to recall every detail about every medication. They test whether you can make clinical decisions: choosing the right drug for the right patient, recognizing when something is going wrong, and knowing what to do next when the first-line treatment fails.

Study drug classes before individual drugs. Understanding the SSRI class (mechanism, shared side effects, shared indications) means you only need to learn the differences between individual SSRIs, not relearn the entire pharmacology for each one. The medication reference pages on this site are structured around this principle: each page teaches what makes that specific medication different from its class, not what it shares with every other member.

Focus on clinical decision points, not pharmacology trivia. The board exam will not ask you to draw the serotonin reuptake mechanism. It will give you a depressed patient with comorbid chronic pain and ask which antidepressant to choose (duloxetine). It will give you a patient on lithium who develops tremor and ask what to do (propranolol, or reduce dose if level allows). Practice questions that test decision-making build the skill the exam actually measures.

Know the dangerous medications cold. Lithium toxicity, clozapine monitoring, MAOI dietary restrictions, serotonin syndrome, NMS, valproate teratogenicity, lamotrigine titration and Stevens-Johnson risk, benzodiazepine withdrawal. These are the pharmacology topics where getting it wrong has consequences. They are also the topics that appear on every version of the exam.

Use multiple modalities. Reading a medication page builds foundational knowledge. Answering practice questions tests whether you can apply it. Reviewing flashcards with spaced repetition builds long-term retention. Using all three together produces better results than any single approach.